Clinical Trial Update: Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating anlotinib in combination with platinum-etoposide as first-line therapy for extensive-stage small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• platinum-etoposide

Snippet

Sponsor: Xiangya Hospital of Central South University | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 2 | Status: UNKNOWN